Business
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
Seasoned leader with global commercialization and marketing expertiseSOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (“Aligos”, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Compa
About this update from Aligos Therapeutics, Inc.
[{"type":"image","alt":"Aligos Therapeutics","displaySize":"","headline":null,"caption":"Aligos Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L8133ghONMF7WN.yZV6tsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955","width":150,"height":50}},"lazy":false},{"type":"text","content":"Seasoned leader with global commercialization and marketing expertise","length":69,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (“Aligos”, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company’s global commercial capabilities and serve as a member of Aligos’ Senior Leadership Team. Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas.","length":654,"tagName":"p"},{"type":"text","content":"“As we continue to progress the Phase 2 B-SUPREME study of pevifoscorvir sodium, we have begun planning for the future and how best to bring this therapy to patients. I am excited to welcome Jim to Aligos as our Chief Commercial Officer who will spearhead our commercial readiness efforts,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “This is an important role for Aligos as we approach late-stage development. Bringing Jim on is another step closer to our vision of delivering better outcomes for patients in need.”","length":579,"tagName":"p"},{"type":"text","content":"“I am thrilled to join Aligos as the company progresses towards late-stage development,” stated Jim Hassard, MBA, Chief Commercial Officer at Aligos. “This is an exciting time for the chronic hepatitis B virus infection field, as next-generation therapies are closer to helping patients in need of better options. I look forward to building the necessary global commercial ...